Business Context and Reporting Period
Company: Myomo, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2021
Reporting Period: Specific event date (October 14, 2021)
Myomo, Inc., a Delaware corporation, reported the entry into material definitive agreements regarding the exercise of investor warrants originally issued in a February 2020 public offering.
Key Financial Metrics
This filing details a specific capital transaction rather than periodic financial performance. Key figures include:
- Expected Gross Proceeds: Approximately $5.1 million from the exercise of investor warrants.
- Shares Exercised: 1,015,798 shares of common stock underlying the warrants.
- Adjusted Exercise Price: Reduced from $7.50 to $5.00 per share for the participating holders.
- Transaction Costs: $284,400 fee paid to financial advisor Roth Capital Partners, LLC.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a current report on a specific event, not a periodic financial statement.
Material Changes
The primary material change is the reduction of the exercise price for specific investor warrants and the subsequent cash exercise of those warrants. This transaction increases the company's cash position by approximately $5.1 million and increases the number of outstanding shares by 1,015,798.
Guidance, Outlook, and Restrictions
Management Commentary: The company engaged Roth Capital Partners as a financial advisor to facilitate the warrant exercise agreements.
Issuance Restriction: The company agreed to a 30-day lock-up period following the date of the Letter Agreements. During this time, subject to limited exceptions, the company will not issue, agree to issue, or announce the issuance of any shares of common stock or common stock equivalents.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard terms of the warrant exercise agreements.
Investor Verification Checklist
- Verify the final closing of the $5.1 million in proceeds and the issuance of the 1,015,798 new shares.
- Confirm the impact of the new share issuance on total outstanding share count and potential dilution.
- Review the 30-day issuance restriction to understand limitations on near-term capital raising activities.
- Check subsequent filings for the actual cash balance impact after deducting the $284,400 advisory fee.